Related Experiment Video

Updated: Apr 27, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1

Devora Champa1, Marika A Russo1, Xiao-Hui Liao1

  • 1Department of Developmental and Molecular BiologyAlbert Einstein College of Medicine, Price Center for Genetic and Translational Medicine, 1301 Morris Park Avenue, Room 302, Bronx, New York 10461, USADepartments of MedicinePediatrics and Committee on GeneticsUniversity of Chicago, Chicago, Illinois, USADepartment of PathologyMemorial Sloan-Kettering Cancer Center, New York, New York, USA.

Endocrine-Related Cancer
|July 12, 2014
PubMed

Insights

Poorly differentiated thyroid tumors resist treatment. A new mouse model shows targeting Bcl2 family proteins and MEK signaling offers a promising therapeutic strategy for aggressive thyroid cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Poorly differentiated thyroid tumors (PDTC) exhibit poor prognosis and therapeutic resistance.
  • Tumor rarity hinders understanding of aggressive mechanisms and drug resistance.
  • Development of novel therapies for aggressive thyroid cancer is critically needed.

Purpose of the Study:

  • To generate and characterize a novel mouse model for poorly differentiated thyroid cancer.
  • To investigate molecular mechanisms of tumor aggressiveness and drug resistance.
  • To identify and test potential therapeutic targets in this aggressive cancer model.

Main Methods:

  • Generated a novel mouse model by activating Kras and deleting p53 in thyroid follicular cells.
  • Morphological and functional characterization of tumors, including similarity to human PDTC.
  • Assessed tumor dependence on MEK/ERK signaling and apoptosis resistance mechanisms.
  • Evaluated targeted therapy with Obatoclax (Bcl2 family inhibitor) and combined therapies.

Main Results:

  • The mouse model consistently develops papillary thyroid cancer progressing to PDTC and anaplastic carcinomas.
  • Tumors exhibit resistance to apoptosis due to high Bcl2a1 and Mcl1 expression.
  • Obatoclax effectively targets these tumors, and Bcl2 inhibition synergizes with MEK inhibition and doxorubicin.

Conclusions:

  • The novel mouse model accurately recapitulates aggressive human thyroid cancer.
  • Bcl2 family proteins represent a druggable target in poorly differentiated thyroid tumors.
  • Combined inhibition of Bcl2 and MEK signaling shows therapeutic potential for aggressive thyroid cancers.
Keywords:
cell deathmouse modelthyroid cancer

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

24.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K